Literature DB >> 27069257

Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis.

Bruno Paiva1, Joaquin Martinez-Lopez2, Luis A Corchete3, Beatriz Sanchez-Vega2, Inmaculada Rapado2, Noemi Puig3, Santiago Barrio2, Maria-Luz Sanchez4, Diego Alignani1, Marta Lasa1, Alfonso García de Coca5, Emilia Pardal6, Alberto Oriol7, Maria-Esther Gonzalez Garcia8, Fernando Escalante9, Tomás J González-López10, Luis Palomera11, José Alonso12, Felipe Prosper1, Alberto Orfao4, Maria-Belen Vidriales3, María-Victoria Mateos3, Juan-Jose Lahuerta2, Norma C Gutierrez3, Jesús F San Miguel1.   

Abstract

Immunoglobulin light-chain amyloidosis (AL) and multiple myeloma (MM) are 2 distinct monoclonal gammopathies that involve the same cellular compartment: clonal plasma cells (PCs). Despite the fact that knowledge about MM PC biology has significantly increased in the last decade, the same does not apply for AL. Here, we used an integrative phenotypic, molecular, and genomic approach to study clonal PCs from 24 newly diagnosed patients with AL. Through principal-component-analysis, we demonstrated highly overlapping phenotypic profiles between AL and both monoclonal gammopathy of undetermined significance and MM PCs. However, in contrast to MM, highly purified fluorescence-activated cell-sorted clonal PCs from AL (n = 9) showed almost normal transcriptome, with only 38 deregulated genes vs normal PCs; these included a few tumor-suppressor (CDH1, RCAN) and proapoptotic (GLIPR1, FAS) genes. Notwithstanding, clonal PCs in AL (n = 11) were genomically unstable, with a median of 9 copy number alterations (CNAs) per case, many of such CNAs being similar to those found in MM. Whole-exome sequencing (WES) performed in 5 AL patients revealed a median of 15 nonrecurrent mutations per case. Altogether, our results show that in the absence of a unifying mutation by WES, clonal PCs in AL display phenotypic and CNA profiles similar to MM, but their transcriptome is remarkably similar to that of normal PCs.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27069257     DOI: 10.1182/blood-2015-10-673095

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.

Authors:  Yujia Wang; Lushuang Xu; Yang Liu; Yuzhe Hu; Qiang Shi; Lixue Jin; Lijun Yang; Pingzhang Wang; Kunshan Zhang; Xiaojun Huang; Qing Ge; Jin Lu
Journal:  Int J Hematol       Date:  2020-10-10       Impact factor: 2.490

Review 2.  Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details.

Authors:  Vaishali Sanchorawala
Journal:  Blood Adv       Date:  2019-01-22

Review 3.  Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders.

Authors:  Gaurav Chatterjee; Sumeet Gujral; Papagudi G Subramanian; Prashant R Tembhare
Journal:  Indian J Hematol Blood Transfus       Date:  2017-04-26       Impact factor: 0.900

4.  Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis - 2021.

Authors:  Marcus V Simões; Fabio Fernandes; Fabiana G Marcondes-Braga; Philip Scheinberg; Edileide de Barros Correia; Luis Eduardo P Rohde; Fernando Bacal; Silvia Marinho Martins Alves; Sandrigo Mangini; Andréia Biolo; Luis Beck-da-Silva; Roberta Shcolnik Szor; Wilson Marques Junior; Acary Souza Bulle Oliveira; Márcia Waddington Cruz; Bruno Vaz Kerges Bueno; Ludhmila Abrahão Hajjar; Aurora Felice Castro Issa; Felix José Alvarez Ramires; Otavio Rizzi Coelho Filho; André Schmidt; Ibraim Masciarelli Francisco Pinto; Carlos Eduardo Rochitte; Marcelo Luiz Campos Vieira; Cláudio Tinoco Mesquita; Celso Dario Ramos; José Soares-Junior; Minna Moreira Dias Romano; Wilson Mathias Junior; Marcelo Iório Garcia Junior; Marcelo Westerlund Montera; Marcelo Dantas Tavares de Melo; Sandra Marques E Silva; Pedro Manoel Marques Garibaldi; Aristóteles Comte de Alencar Neto; Renato Delascio Lopes; Diane Xavier de Ávila; Denizar Viana; José Francisco Kerr Saraiva; Manoel Fernandes Canesin; Glaucia Maria Moraes de Oliveira; Evandro Tinoco Mesquita
Journal:  Arq Bras Cardiol       Date:  2021-09       Impact factor: 2.000

5.  Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans.

Authors:  Andrew Staron; Luke Zheng; Gheorghe Doros; Vaishali Sanchorawala
Journal:  Blood Cancer J       Date:  2022-07-04       Impact factor: 9.812

6.  Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

Authors:  Efstathios Kastritis; Ioannis V Kostopoulos; Evangelos Terpos; Bruno Paiva; Despina Fotiou; Maria Gavriatopoulou; Nikolaos Kanellias; Dimitrios C Ziogas; Maria Roussou; Magdalini Migkou; Evangelos Eleutherakis-Papaiakovou; Ioannis P Trougakos; Ourania Tsitsilonis; Meletios A Dimopoulos
Journal:  Blood Cancer J       Date:  2018-05-24       Impact factor: 11.037

Review 7.  Light Chain Amyloidosis.

Authors:  Paolo Milani; Giampaolo Merlini; Giovanni Palladini
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-03-01       Impact factor: 2.576

Review 8.  Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications.

Authors:  Linchun Xu; Yongzhong Su
Journal:  Exp Hematol Oncol       Date:  2021-07-20

Review 9.  Current applications of multiparameter flow cytometry in plasma cell disorders.

Authors:  T Jelinek; R Bezdekova; M Zatopkova; L Burgos; M Simicek; T Sevcikova; B Paiva; R Hajek
Journal:  Blood Cancer J       Date:  2017-10-20       Impact factor: 11.037

10.  Identification of Candidate Genes and Therapeutic Agents for Light Chain Amyloidosis Based on Bioinformatics Approach.

Authors:  Wenxiang Bai; Honghua Wang; Hua Bai
Journal:  Pharmgenomics Pers Med       Date:  2019-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.